Surgery Partners Earnings Perspective: Return On Invested Capital
Pulled from Benzinga Pro data, Surgery Partners (NASDAQ:SGRY) posted Q1 earnings of $42.80 million, an increase from Q4 of 0.23%. Sales dropped to $596.20 million, a 2.29% decrease between quarters.
Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell
• Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
55 Biggest Movers From Friday
Gainers
Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals engaged Ladenburg Thalmann & Co Inc to evaluate strategic alternatives for the Company to maximize shareholder value.
HCA Healthcare’s Softer Guidance Pulls Hospital Peers Down
Earlier today HCA Healthcare Inc (NYSE: HCA) reported Q1 earnings and cut FY22 guidance.
The revised outlook is based on current expectations regarding the impact of the COVID-19 pandemic and related government legislation, labor cost, and inflation.
35 Stocks Moving In Friday’s Mid-Day Session
Gainers
Blueknight Energy Partners, L.P. (NASDAQ: BKEP) shares climbed 38.9% to $4.5701 after the company announced it will be acquired by its general partner Ergon.
Where Surgery Partners Stands With Analysts
Within the last quarter, Surgery Partners (NASDAQ:SGRY) has observed the following analyst ratings:
SVB Leerink Maintains Outperform on Surgery Partners, Raises Price Target to $65
SVB Leerink analyst Whit Mayo maintains Surgery Partners (NASDAQ:SGRY) with a Outperform and raises the price target from $63 to $65.
Surgery Partners Q4 Sales $610.20M Miss $621.74M Estimate
Surgery Partners (NASDAQ:SGRY) reported quarterly sales of $610.20 million which missed the analyst consensus estimate of $621.74 million by 1.86 percent. This is a 11.29 percent increase over sales of $548.30 million
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell
• Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.